Biora Therapeutics/BIOR

$0.61

0.4%
-
1D1W1MYTD1YMAX

About Biora Therapeutics

Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.

Ticker

BIOR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Aditya Mohanty

Employees

58

Headquarters

San diego, United States

BIOR Metrics

BasicAdvanced
$20.47M
Market cap
-
P/E ratio
-$8.56
EPS
1.27
Beta
-
Dividend rate
$20.47M
1.27019
$6.70
$0.59
446.31K
0.303
-293.45%
5,118.662
-98.69%
-34.13%
-70.88%

What the Analysts think about BIOR

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 2 analysts.
1,588.52% upside
High $15.00
Low $5.60
$0.61
Current price
$10.30
Average price target

BIOR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-15.4M
-79.02%
Profit margin
0%
-

BIOR Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 4.2%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.47
-$4.89
-$0.62
-
Expected
-$1.60
-$0.93
-$0.60
-$0.45
Surprise
-8.13%
428.65%
4.2%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Biora Therapeutics stock?

Biora Therapeutics (BIOR) has a market cap of $20.47M as of April 23, 2024.

What is the P/E ratio for Biora Therapeutics stock?

The price to earnings (P/E) ratio for Biora Therapeutics (BIOR) stock is 0 as of April 23, 2024.

Does Biora Therapeutics stock pay dividends?

No, Biora Therapeutics (BIOR) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Biora Therapeutics dividend payment date?

Biora Therapeutics (BIOR) stock does not pay dividends to its shareholders.

What is the beta indicator for Biora Therapeutics?

Biora Therapeutics (BIOR) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Biora Therapeutics stock price target?

The target price for Biora Therapeutics (BIOR) stock is $10.3, which is 1588.52% above the current price of $0.61. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Biora Therapeutics stock

Buy or sell Biora Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing